ArticleActa naturae
Dimephosphon Radioprotective Properties on the Model of Radiation Injury In Vivo.
Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation therapy is a commonly used cancer treatment modality. However, its application is limited because of its toxicity to healthy tissue. The search for effective radioprotective agents remains one of the key goals of radiation oncology and radiobiology. This study focuses on experimental modeling of radiation injury in animals and the investigation of Dimephosphon radioprotective properties, a drug exhibiting anti-acidotic, antitumor, and antioxidant activities. It was shown that 14-day administration of the drug at a dose of 750 mg/kg after single-dose (5 Gy) irradiation of CD-1 mice resulted in a local radioprotective effect, reducing the severity of the radiation-induced injury to the intestinal epithelium and splenic capsule. The results of metabolomic screening revealed that the levels of the key metabolites responsible for antioxidant properties such as alpha-tocopherol, nicotinamide riboside, N-carbamoyl-L-aspartate, and adenylosuccinate were significantly increased, indicating that the Dimephosphon drug provides enhanced antioxidant protection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.